Emendo Biotherapeutics Raises $61 Million to Advance Next Generation Genome Editing Therapeutics

NEW YORK--(BUSINESS WIRE)--Emendo Biotherapeutics, a leader in next-generation gene editing using synthetic biology to address untreatable diseases, today announced a Series B investment totaling $61 million led by AnGes, Inc., a Japan-based biopharma, reflecting its strategic interest in partnering with Emendo on the development of specific indications. “This financing provides a strong foundation from which we can accelerate our proprietary OMNI gene editing platform towards a broad clinical